Hematological Clozapine Monitoring With a Point-of-care Device (CHEMPAQ)

University of Aarhus

Status: Completed

Conditions: Schizophrenia

Treatments: Device: Venous blod sample; Device: CHEMPAQ

Study type: Observational

Funder types: Other

Identifiers

NCT01138618

1.5 - 01 MARCH2010

Details and patient eligibility

About

Clozapine remain the drug of choice for treatment resistant schizophrenia and up to 60% of patients not responding to other antipsychotics will respond to clozapine. However, the use of clozapine is restricted due to the risk of agranulocytosis and consequently the need for mandatory hematological monitoring. CHEMPAQ XBC is a point-of-care device that can be used in patients home and analyze WBC and granulocytes by a single capillary blood drop. This study aims to investigate whether this new procedure increases the acceptability of clozapine

Enrollment: 85 patients

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Treated with clozapine
• Compliant with blood monitoring
• Willing to give informed consent

Exclusion criteria

• Prior case of agranulocytosis

Trial design

85 participants in 2 patient groups

CHEMPAQ-venous-CHEMPAQ-venous

Description:

The two arms only differ in order of kind of blood samples.

Treatment:

Device: Venous blod sample

Device: CHEMPAQ

Venous-CHEMPAQ-Venous-CHEMPAQ

Description:

The two arms only differ in order of kind of blood samples.

Treatment:

Device: Venous blod sample

Device: CHEMPAQ